By Nana O 
A groundbreaking study has identified a specific subset of immune cells that actively support the proliferation and aggressiveness of glioblastoma, the most lethal and treatment-resistant form of brain cancer. This pivotal discovery, spearheaded by researchers at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine, offers critical new insights into the intricate tumor-immune microenvironment and presents promising avenues for future therapeutic interventions.
Unveiling the Symbiotic Relationship in Glioblastoma
Glioblastoma (GBM) is a formidable adversary, characterized by its rapid growth, diffuse infiltration into brain tissue, and a starkly poor prognosis, with a median survival rate often measured in months. Despite decades of research and advancements in treatment modalities, including surgery, radiation therapy, and chemotherapy, the inherent resistance of these tumors to conventional therapies remains a significant challenge. A key factor contributing to this resistance is the tumor’s ability to manipulate the immune system, creating an immunosuppressive environment that shields it from immune attack and fosters its unchecked expansion.
The recent research, published on January 17th in the prestigious journal Science, delved into the complex cellular landscape of glioblastomas, particularly focusing on the most aggressive, grade 4 tumors. Leveraging a cutting-edge technology known as spatial genomics, which allows for the simultaneous analysis of gene expression and cellular location, the investigators sought to understand the precise interactions between tumor cells and the immune cells within the tumor microenvironment. Their meticulous investigation revealed a striking co-localization between glioblastoma stem cells (GSCs) – the elusive population of cells believed to drive tumor recurrence and heterogeneity – and a specific type of immunosuppressive immune cell known as myeloid-derived suppressor cells (MDSCs).
"Tumor stem cells represent only 5% to 10% of the tumor, but they’re the critical cells that are renewing and generating the rest of the tumor and are essentially responsible for the aggressiveness of the tumor," explained senior study author Drew Pardoll, M.D., Ph.D., the Martin D. Abeloff Professor of Cancer Research and director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy. "We found that the myeloid-derived suppressor cells and tumor stem cells literally were in the same place – a region described by pathologists in the 1980s as the pseudopalisading region. There was a very intimate connection." This "pseudopalisading" refers to a characteristic pattern of tumor cells surrounding areas of necrosis, a feature often observed in high-grade gliomas. The discovery of MDSCs residing in such close proximity to these critical GSCs suggests a direct and critical role in the tumor’s survival and progression.
Advanced Technologies Illuminate Cellular Dialogue
To achieve this level of cellular resolution, the research team employed a multi-pronged approach, beginning with single-cell RNA sequencing on tissue samples from 33 diverse brain tumors, ranging from low-grade to high-grade malignancies. This initial analysis helped to broadly characterize the immune cell populations present. Subsequently, the researchers utilized spatial transcriptomics, a revolutionary technique that maps gene expression patterns within the spatial context of a tissue sample. This allowed them to analyze over 750,000 immune cells and more than 350,000 tumor and associated cells within the glioblastoma samples. The results were unequivocal: MDSCs were not randomly distributed but were found to be intimately associated with the glioblastoma stem cells.
Christina Jackson, M.D., an assistant professor of neurosurgery at the Perelman School of Medicine at the University of Pennsylvania, who was at Johns Hopkins during the research and served as the first and co-corresponding author, highlighted the significance of this finding in the context of GBM’s notorious immune evasion. "Glioblastoma is a highly aggressive brain tumor with remarkable ability to evade the immune system, which has made immune-based therapies largely ineffective to this point," Dr. Jackson stated. "Our study revealed a distinct subset of immune cells, known as myeloid-derived suppressor cells that promote glioblastoma growth, providing new insights into how the tumor interacts with the immune system. By identifying these cells and their role, we hope to uncover new therapeutic targets and lay the groundwork for more effective treatments."
The research meticulously detailed a reciprocal, symbiotic relationship between GSCs and MDSCs. The study found that GSCs actively recruit and nurture MDSCs by producing specific chemical signals known as chemokines. Furthermore, GSCs were observed to generate growth and activation factors that directly benefit the MDSCs. In return, the MDSCs reciprocated by releasing growth factors that fuel the proliferation and survival of the tumor cells themselves. This cyclical interaction effectively creates a self-sustaining ecosystem within the tumor, promoting its relentless growth and resistance to therapeutic interventions.
Identifying Key Molecular Mediators
Delving deeper into the molecular underpinnings of this cellular alliance, the investigators identified specific molecules produced by GSCs that act as powerful attractants and activators for MDSCs. Among the key culprits identified were interleukin-6 (IL-6) and interleukin-8 (IL-8). Both IL-6 and IL-8 are well-established cytokines involved in inflammatory responses and are known to bind to specific receptors on MDSCs, thereby facilitating their recruitment and activation within the tumor microenvironment.
"IL-8 is one of the major attractants to bring the MDSCs to the tumor, and IL-6 is one of the major activators of the MDSCs," Dr. Pardoll elaborated. This precise identification of molecular signaling pathways opens up exciting possibilities for targeted therapies designed to disrupt this crucial interaction.
Adding another significant layer to their findings, the research team discovered that MDSCs, in turn, secrete a previously unrecognized growth factor, fibroblast growth factor 11 (FGF11), which directly nourishes the GSCs. This marks the first instance of FGF11 being implicated in the progression of brain cancers or any other malignancy, underscoring the novelty and potential impact of this discovery.
Correlation with Tumor Aggressiveness and Survival
The study also explored the presence of MDSCs in less aggressive brain tumors, specifically those with a mutation in the IDH1 gene. These IDH-mutant gliomas are generally considered less aggressive and have a better prognosis than their IDH-wildtype counterparts. The researchers observed that tumors with the IDH1 mutation exhibited a marked paucity of MDSCs and significantly fewer GSCs, reinforcing the association between these immune cells and tumor malignancy.
To further validate this correlation, the team analyzed data from the National Cancer Institute’s Cancer Genome Atlas (TCGA) database, a comprehensive repository of genomic data from a wide range of cancer types. Their analysis confirmed a robust correlation between the infiltration of MDSCs and patient survival across various brain cancers. Specifically, tumors with lower levels of GSCs and MDSCs were associated with significantly better patient outcomes. This observation not only strengthens the role of MDSCs as key drivers of glioblastoma but also suggests their potential as a prognostic biomarker, offering valuable information about a patient’s likely trajectory and response to treatment.
Implications for Future Cancer Therapies
The implications of this research are profound, offering a new paradigm for understanding and potentially treating aggressive brain tumors. By identifying the intricate symbiotic relationship between GSCs and MDSCs, and the molecular players that mediate this interaction, the study presents several promising new targets for therapeutic intervention.
"While additional studies are needed to further understand these cellular interactions, the work is exciting in that it suggests additional potential targets to block in treatment of these aggressive brain tumors," Dr. Pardoll stated.
One such promising avenue involves disrupting the IL-6 and IL-8 signaling pathways. Notably, Jamie Spangler, Ph.D., an associate professor of biomedical engineering at Johns Hopkins, has already developed an investigational bispecific antibody designed to bind to the receptors for both IL-6 and IL-8, effectively blocking their signaling. This development, directly informed by the findings of this study, represents a tangible step towards translating these scientific discoveries into clinical applications. Blocking these key attractants and activators could potentially starve the MDSCs of their signals and prevent their accumulation within the tumor microenvironment, thereby disarming the tumor’s immune-evasive capabilities and making it more vulnerable to other therapies.
Furthermore, targeting FGF11, the growth factor secreted by MDSCs, could represent another novel therapeutic strategy to directly inhibit the sustenance of GSCs. The identification of this previously uncharacterized molecule in cancer progression opens up an entirely new frontier for drug development.
A Collaborative Endeavor and Funding Support
This extensive research effort was a testament to extensive collaboration among numerous investigators. Key study co-authors from Johns Hopkins included Christopher Cherry, Sadhana Bom, Arbor Dykema, Rulin Wang, Elizabeth Thompson, Ming Zhang, Runzhe Li, Zhicheng Ji, Wenpin Hou, Wentao Zhan, Hao Zhang, John Choi, Ajay Vaghasia, Landon Hansen, Kate Jones, Fausto Rodriguez, Jon Weingart, Calixto-Hope Lucas, Jonathan Powell, Jennifer Elisseeff, Srinivasan Yegnasubramanian, Chetan Bettegowda, and Hongkai Ji. The research also benefited from contributions by researchers at Stanford University School of Medicine in California.
The groundbreaking work was generously supported by grants from the National Institutes of Health (grants #F32NS108580, #R01HG010889, R01HG009518, RA37CA230400, U07CA230691), the Neurosurgery Research Education Foundation, the Bloomberg~Kimmel Institute for Cancer Immunotherapy, the Mark Foundation for Cancer Research, a Burroughs Wellcome Career Award for Medical Scientists, the Commonwealth Foundation, the Maryland Cigarette Restitution Fund, and the NIH Pioneer Award. These diverse funding sources underscore the broad recognition of the importance and potential impact of this research.
The article also disclosed potential conflicts of interest for several researchers involved, detailing their consulting roles, grant support, equity ownership, and board memberships with various pharmaceutical and biotechnology companies. These disclosures, managed by The Johns Hopkins University in accordance with its conflict-of-interest policies, are standard practice in scientific publications and reflect the active engagement of these researchers in the broader cancer research and development landscape. The transparency surrounding these relationships ensures the integrity and objectivity of the published findings.
In conclusion, the identification of this critical immune cell population and its symbiotic relationship with glioblastoma stem cells marks a significant leap forward in our understanding of brain cancer biology. This discovery not only elucidates a key mechanism by which these aggressive tumors evade immune surveillance and promote their own growth but also provides a fertile ground for the development of novel, targeted therapies that could ultimately improve outcomes for patients facing this devastating disease. The ongoing research and development of targeted agents, such as the bispecific antibody targeting IL-6 and IL-8, offer tangible hope for a future where glioblastoma is more effectively managed and treated.
